SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Boyce Burge who wrote (385)6/5/1997 7:38:00 PM
From: NeuroInvestment   of 998
 
1) CEPH has two small molecule neurotrophin mimetic/stimulant programs:one is the receptor kinase program from which CEP1347 has sprung; the other is the NEM class which cause the production of NGF. They have plenty of competition, and I am particularly impressed with GLFD's neuroimmunophilin programs, but the CEPH molecules have promise.
2) It is true that companies emphasizing large molecule neurotrophins must diversify or die. That is why REGN has moved so strongly into non-CNS targets. I believe that the selloff of CTII is short-sighted; having the ability to deliver almost anything (including neurotrophic factors) to selected targets in the brain (and eye) is very appealing. We do not yet know what a general infusion of neurotrophic stimulants throughout the CNS means on a longterm basis. While receptor systems are location and function specific, one still runs the risk of unexpected trophic reactions. CTII's targetting is not dead by any means. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News